News Quantified

HCM – hutchmed (china) limited - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma [Yahoo! Finance]

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

Form 6-K HUTCHMED (China) Ltd For: Dec 31

Form 6-K HUTCHMED (China) Ltd For: Dec 30

Form 6-K HUTCHMED (China) Ltd For: Dec 29

Form 6-K HUTCHMED (China) Ltd For: Dec 17

Form 6-K HUTCHMED (China) Ltd For: Dec 08

Top News Gainers

3/13 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 10.3%

10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%

4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%

9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%

2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%

7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%

4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%

10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%

1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%

3/3 Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool] 2.9%

Top News Decliners

6/27 Chi-Med Announces Secondary Offering of American Depositary Shares -18.8%

3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%

1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%

1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%

7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%

9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%

12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%

2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%

9/27 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -2.9%

6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day